Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosis.

There was a statistically borderline significant difference in time to first exacerbation in favor of patients with no AE(s) to nintedanib (P=0.049) with no higher exacerbation risk in patients experiencing AE(s) ( Figure S10A,S10B ).

also in 11,409 other papers